Business Context and Reporting Period
This Form 8-K reports on the results of the 2019 Annual Meeting of Stockholders for Inmune Bio, Inc., held on September 12, 2019. The company is an emerging growth company incorporated in Nevada with its principal executive offices in La Jolla, California. A total of 8,749,576 shares, representing 81.21% of the capital stock outstanding as of the record date, were represented at the meeting.
Key Financial Metrics
This filing is a current report regarding corporate governance and shareholder voting results. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
The following matters were voted upon and approved by the stockholders:
- Director Elections: All six nominees (Edgardo Baracchini, J. Kelly Ganjei, Scott Juda, Tim Schroeder, David Szymkowski, and Raymond J. Tesi) were elected with overwhelming support (approximately 99.5% FOR votes).
- Equity Incentive Plan: The 2019 Equity Incentive Plan was approved, reserving 2,000,000 shares of common stock.
- Independent Auditor: The appointment of Marcum LLP as the independent registered public accounting firm for the year ending December 31, 2019, was ratified.
- At-the-Market Offering (LPC Transaction): Stockholders approved the potential issuance and sale of more than 20% of common stock pursuant to an agreement with Lincoln Park Capital Fund LLC (LPC) to purchase up to $20,000,000 of the company's stock.
- Executive Compensation (Say-on-Pay): The advisory vote on named executive officer compensation was approved.
- Compensation Vote Frequency (Say-on-Frequency): Stockholders recommended a three-year frequency for future advisory votes on executive compensation.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, or specific risk factors. The primary operational implication of the approved LPC Nasdaq Proposal is the authorization for the company to issue shares up to a $20 million aggregate value through an agreement with Lincoln Park Capital Fund LLC, subject to the company's sole discretion.
Key Facts for Investor Verification
- Verify the terms of the agreement with Lincoln Park Capital Fund LLC regarding the $20 million at-the-market offering.
- Confirm the number of shares reserved under the newly approved 2019 Equity Incentive Plan (2,000,000 shares).
- Review the composition of the newly elected Board of Directors.
- Check subsequent filings for the actual issuance of shares under the LPC agreement.